Replies to post #207894 on Biotech Values

[xavierprivas]

GSK filed on June 30 2016 for inter partes review of FGEN Patent 8,609,646 was denied review by the Patent Office today. Explain why FGEN is up while
most biotechs go down

This is just one patent out the six that Glaxo requested a ipr.
(8,466,172; 8,614,204; 8,629,131; 8,604,012; 8,609,646; and 8,604,013)